Richardpruen (talk | contribs) (→Suggested additions to this page: added extracts) |
Richardpruen (talk | contribs) (→Suggested additions to this page: added bullet points) |
||
| Line 1,307: | Line 1,307: | ||
===2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183099/ Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials]=== | ===2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183099/ Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials]=== | ||
* Studies show that the penetration of SARS-CoV-2 into upper respiratory tract, bronchial and pulmonary cells involve transmembrane receptor ACE2, which probably interacts with acetylcholine nicotinic receptors of the α7 subtype. The mechanism of the interactions remains hypothetical. | |||
* Despite a relatively safe tolerance profile, transdermal nicotine therapy in non-smokers can only be used in clinical trials. There is a lack of formal assessment of the potential risk of developing a tobacco addiction. This review offers baseline data to set a transdermal nicotine protocol for non-smokers with a new purpose. | * Despite a relatively safe tolerance profile, transdermal nicotine therapy in non-smokers can only be used in clinical trials. There is a lack of formal assessment of the potential risk of developing a tobacco addiction. This review offers baseline data to set a transdermal nicotine protocol for non-smokers with a new purpose. | ||
* Analyses of nicotine administration protocols and safety were conducted after reviewing Medline and Science Direct databases performing a search using the words [transdermal nicotine] AND [non-smoker] AND selected diseases. | * Analyses of nicotine administration protocols and safety were conducted after reviewing Medline and Science Direct databases performing a search using the words [transdermal nicotine] AND [non-smoker] AND selected diseases. | ||
edits